Immunotherapy and Epigenetic Pathway Modulation in Glioblastoma Multiforme
Glioblastoma Multiforme (GBM) is the most common malignant primary brain tumor. Despite aggressive multimodality treatment it remains one of the most challenging and intractable cancers (1]. While current standard of care treatment for GBM is maximal safe surgical resection, systemic chemotherapy wi...
Main Authors: | Christopher Chin, Emma S. Lunking, Macarena de la Fuente, Nagi G. Ayad |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2018-11-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fonc.2018.00521/full |
Similar Items
-
Viral Control of Glioblastoma
by: Nicole Mihelson, et al.
Published: (2021-06-01) -
Epigenetic Targeting of Glioblastoma
by: Massimo Romani, et al.
Published: (2018-10-01) -
Identification of a multidimensional transcriptome signature for survival prediction of postoperative glioblastoma multiforme patients
by: Wei-Zhen Gao, et al.
Published: (2018-12-01) -
Epigenetic pathways and plasticity in brain tumors
by: Robert K. Suter, et al.
Published: (2020-11-01) -
Current Immunotherapies for Glioblastoma Multiforme
by: Boyuan Huang, et al.
Published: (2021-03-01)